SCHEMBL1679319

SCHEMBL1679319

CCn1c(=NN=c2sc3cc(S(=O)(=O)O)ccc3n2CC)sc2ccccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.47
NPSR1 Q6W5P4 6/20 0.47
TSHR P16473 3/20 0.47
MAPK1 P28482 1/20 0.47
KCNQ3 O43525 1/20 0.45
KCNQ2 O43526 1/20 0.45
MAPT P10636 4/20 0.45
HPGD P15428 8/20 0.41
KDM4E B2RXH2 7/20 0.41
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
RECQL P46063 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 1/20 0.41
LMNA P02545 2/20 0.40
PPARG P37231 2/20 0.40
NCOA2 Q15596 2/20 0.40
NCOA1 Q15788 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18785100 1.00 ALDH1A1 (0.47) ALDH1A1NPSR1TSHRMAPK1KCNQ3
SCHEMBL15849845 1.00 ALDH1A1 (0.47) ALDH1A1NPSR1TSHRMAPK1KCNQ3
SCHEMBL30132089 0.94 MAPT (0.48) ALDH1A1NPSR1TSHRMAPK1MAPT
SCHEMBL432548 0.94 MAPT (0.48) ALDH1A1NPSR1TSHRMAPK1MAPT
SCHEMBL13458992 0.94 MAPT (0.48) ALDH1A1NPSR1TSHRMAPK1MAPT
SCHEMBL7915441 0.94 MAPT (0.48) ALDH1A1NPSR1TSHRMAPK1MAPT
SCHEMBL14599149 0.94 MAPT (0.48) ALDH1A1NPSR1TSHRMAPK1MAPT
SCHEMBL63297 0.94 MAPT (0.48) ALDH1A1NPSR1TSHRMAPK1MAPT
Hydrogen Peroxide SCHEMBL5566292 0.92 MAPT (0.47) ALDH1A1NPSR1TSHRMAPK1MAPT
Ammonia Solution, Strong SCHEMBL2319900 0.92 MAPT (0.47) ALDH1A1NPSR1TSHRMAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4722893-A Reagents for enzyme immunoassay for apolipoprotein B SHIRAIMATSU SHINYAKU KABUSHIKI KAISHA (JP) 1988-02-02 US claimed
US-10036098-B2 Method for determining an analyte content of a liquid sample by means of a bioanalyzer ENDRESS+HAUSER CONDUCTA GMBH+CO. KG (DE) 2018-07-31 US disclosed
EP-2310403-B1 NEW BACTERIOPHAGE ADHESION PROTEINS BIOMÉRIEUX S A (FR) 2017-12-06 EP disclosed
US-20170072069-A1 BIOACTIVE AGENTS UNDER WATER DISPERSIBLE SOLID FORMS FOR FOOD, NUTRACEUTICAL, AGRICULTURAL AND PHARMACEUTICAL APPLICATIONS B-ORGANIC FILMS CORP. (CA) 2017-03-16 US disclosed
EP-3124492-A1 NEW BACTERIOPHAGE ADHESION PROTEINS bioMérieux S.A. (FR) 2017-02-01 EP disclosed
EP-2721150-B1 POLYHEDRAL CAGE-CONTAINING MESOPOROUS METAL-ORGANIC FRAMEWORKS AS PLATFORM FOR BIOCATALYSIS, METHODS OF MAKING THESE FRAMEWORKS, AND METHODS OF USING THESE FRAMEWORKS UNIV SOUTH FLORIDA (US) 2016-12-07 EP disclosed
US-9404105-B2 Polyhedral cage-containing mesoporous metal-organic frameworks as platform for biocatalysis, methods of making these frameworks, and methods of using these frameworks UNIVERSITY OF SOUTH FLORIDA (US) 2016-08-02 US disclosed
US-9394534-B2 Method and means for enrichment, removal and detection of gram-positive bacteria BIOMERIEUX S.A. (FR) 2016-07-19 US disclosed
EP-2601291-B1 A NOVEL GLUCOSE OXIDASE BRAIN BIOTECHNOLOGY RES & INFORMATION NETWORK AG (DE) 2015-11-25 EP disclosed
US-20150087044-A1 POLYHEDRAL CAGE-CONTAINING MESOPOROUS METAL-ORGANIC FRAMEWORKS AS PLATFORM FOR BIOCATALYSIS, METHODS OF MAKING THESE FRAMEWORKS, AND METHODS OF USING THESE FRAMEWORKS UNIVERSITY OF SOUTH FLORIDA 2015-03-26 US disclosed
US-5824474-A Method for detecting nucleic acid FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1998-10-20 US disclosed
EP-0453055-B1 Antigenic proteins and vaccines containing them for prevention of coccidiosis DIMMINACO AG SA LTD (CH) 1997-09-03 EP disclosed
EP-0725149-A1 METHOD OF DETECTING NUCLEIC ACID FUSO PHARMACEUTICAL INDUSTRIES LTD. (JP) 1996-08-07 EP disclosed
EP-0453054-B1 Antigenic proteins and vaccines containing them for prevention of coccidiosis SOLVAY (BE) 1996-07-03 EP disclosed
EP-0453054-A2 Antigenic proteins and vaccines containing them for prevention of coccidiosis SOLVAY (Société Anonyme) (BE) 1991-10-23 EP disclosed
EP-0453055-A2 Antigenic proteins and vaccines containing them for prevention of coccidiosis SOLVAY (Société Anonyme) (BE) 1991-10-23 EP disclosed
EP-0155141-B1 STANDARD MATERIALS FOR MEASUREMENT OF IMMUNE COMPLEXES AND METHOD FOR MEASUREMENT OF IMMUNE COMPLEXES TEIJIN LIMITED (JP) 1990-12-05 EP disclosed
US-4945039-A Standard materials for measurement of immune complexes and method for measurement of immune complexes TEIJIN LIMITED (JP) 1990-07-31 US disclosed
US-4722893-A Reagents for enzyme immunoassay for apolipoprotein B SHIRAIMATSU SHINYAKU KABUSHIKI KAISHA (JP) 1988-02-02 US disclosed
EP-0155141-A2 Standard materials for measurement of immune complexes and method for measurement of immune complexes TEIJIN LIMITED (JP) 1985-09-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170072069-A1 BIOACTIVE AGENTS UNDER WATER DISPERSIBLE SOLID FORMS FOR FOOD, NUTRACEUTICAL, AGRICULTURAL AND PHARMACEUTICAL APPLICATIONS GYS2, GHDC, SFPQ ALDH1A1 4351/4885NPSR1 3456/4885TSHR 4728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.